GP9 and hemophilia A: [43] confirmed that a combination of APCC or rFVIIa with emicizumab is related to the activation of the coagulation cascade and that disturbances in other functional processes, including the complement system, fibrinogenesis (fibrinogen α, β, and γ chain), and the major platelet adhesive receptor glycoproteins (GP1bα, GPV, and GPIX), might explain the occurrence of drug-induced TMA in some persons with hemophilia A treated with emicizumab plus APCC.